Barrett's oesophagus: An audit of surveillance over a 17-year period

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 3, 2006, Pages 271-276

  Gladman, Lisa ^a   Chapman, Warren ^a   Iqbal, Tariq H ^a   Gearty, Joan C ^a   Cooper, Brian T ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

Audit; Barrett's oesophagus; Cancer incidence; Endoscopic surveillance

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; DEATH; DYSPLASIA; ENDOSCOPY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; INCIDENCE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; TISSUE SECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; HISTAMINE H2 ANTAGONISTS; HOSPITALS, TEACHING; HUMANS; MALE; MEDICAL AUDIT; METAPLASIA; MIDDLE AGED; PATIENT SELECTION; PROTON PUMPS; RETROSPECTIVE STUDIES;

EID: 33644590229     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200603000-00007     Document Type: Article

References (47)

1. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus; functional assessment, proposed pathogenesis and surgical therapy. Arch Surg 1983; 118:543-549.
2. Cooper BT, Barbezat GO. Barrett's oesophagus. A clinical study of 52 cases. QJ Med 1987; 62:97-108.
3. Tytgat GNJ, Hammeetman W, Onstenk RR, Scotberg R. The spectrum of columnar lined (Barrett's) oesophagus. Endoscopy 1989; 21:177-185.
4. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histological spectrum of Barrett's esophagus. N Engl J Med 1976; 295:476-480.
5. Rothery GA, Patterson JE, Stoddard CJ, Day DW. Histological and histochemical changes in the columnar lined (Barrett's) oesophagus. Gut 1986; 27:1062-1068.
6. Skinner DB, Walther BC, Riddell RH, Schmid H, Iascone C, DeMeester TR. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983; 198:554-565.
7. Spechler SJ, Robbins AH, Rubin HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87:927-935.
8. Kerlin P, Mellow GD, van Deth A. Barrett's oesophagus. Clinical endoscopic and histologic spectrum in 50 cases. Austral NZ J Med 1986; 16:198-205.
9. Reid BJ, Haggitt RG, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk of adenocarcinoma. Gastroenterology 1987; 93:1-11.
10. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104:510-513.
11. Blot WJ, DiBisceglia AM, Kieely RW, Fraumani JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1993; 265:1297-1299.
12. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing Barrett's oesophagus: education, enthusiasm or epidemiology? Lancet 1997; 350:933.
13. Conio M, Cameron AJ. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmstead county. Gut 2001; 48:304-309.
14. Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97:1888-1895.
15. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's oesophagus? Gastroenterology 2000; 119:333-338.
16. Jankowski JA, Provenzale D, Moayeddi P. Esophageal adenocarcinoma arising from Barrett's metaplasia: regional variations in the West. Gastroenterology 2002; 122:588-591.
17. McDonald CE, Wickes ALB, Playfair RJ. 10 Year experience of screening patients with Barrett's oesophagus in a university hospital. Gut 1997; 41:303-307.
18. McDonald CE, Wickes ALB, Playfair RJ. Final results of 10 year cohort of patients undergoing surveillance for Barrett's oesophagus. BMJ 2000; 321:1252-1255.
19. Wright TA, Gray MR, Morris AI, Gilmore IT, Smart HL, Myskow M, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996; 39:574-579.
20. McGarrity T. Barrett's oesophagus. The continuing conundrum. BMJ 2000; 321:1238-1239.
21. Paraf F, Flejou JF, Potet F, Molas G, Fehali F. Esophageal squamous carcinoma in 5 patients with Barrett's esophagus. Am J Gastroenterol 1992; 87:746-750.
22. Basu KK, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol 2004; 16:171-175.
23. El-Agib A, Mohammed I, Cooper BT, Trudgill N. Endoscopic surveillance for Barrett's esophagus. The patient's perspective [Abstract]. Gastroenterology 2004; 126:A178.
24. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053.
25. Naef AP, Savary M, Ozziello L. Columnar lined lower esophagus: an acquired lesion with malignant potential. J Thorac Cardiovasc Surg 1975; 70:826-835.
26. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar lined (Barrett's) esophagus. N Engl J Med 1985; 313:857-859.
27. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
28. Bani Hani K, Sue-Ling H, Johnson D, Axon ATR, Martin IG. Barrett's oesophagus: results from a 13 year surveillance programme. Eur J Gastroenterol Hepatol 2000; 12:649-654.
29. Murray L, Watson P, Johnston B, Sloan J, Mainie IML. Risk of adenocarcinoma in Barrett's oesophagus: a population based study. BMJ 2003; 327:534-535.
30. Solaymani-Dodaran M, Logan RFA, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53:1070-1074.
31. Ouatu-Lascar R, Fitzgerald RC, Triadafilopolous G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117:327-335.
32. Hammeetman W, Tytgat GNJ, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96:1249-1256.
33. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow cytometry and histological progression to malignancy in Barrett's esophagus. Gastroenterology 1992; 102:1212-1219.
34. Vieth M, Stolte M. Barrett's esophagus and neoplasia. Gastroenterology 2002; 122:590.
35. Eisen GM, Lieberman DA, Fennerty MB, Sonnenberg A. Screening and surveillance in Barret's esophagus. A call to action. Clin Gastroenterol Hepatol 2004; 2:861-864.
36. Perdue DG, Murray J, Wang KK. The wizards of odds: cost effectiveness model, Barrett's screening and surveillance guidelines. Clin Gastroenterol Hepatol 2004; 2:865-867.
37. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111:33-37.
38. Anderson LA, Murray LJ, Murphy SJ, Fitzpatrick DA, Johnston BT, Watson P, et al. Mortality in Barrett's oesophagus. Gut 2003; 52:1081-1084.
39. Burgh A, van der, Hoop WCJ, van Blankenstein M. Oesophageal carcinoma is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39:5-8.
40. Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and non-surveyed patients. J Thorac Cardiovasc Surg 1994; 108:813-822.
41. Sandwick JW, van Lanschot JJB, Kuiken BW, Tytgat GNJ, Offerhaus GJA, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43:216-222.
42. Corley DA, Levine TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population based study. Gastroenterology 2002; 122:633-640.
43. Inadomi JM, Sampliner RE, Lagergren J, Lieberman D, Fendrick AM, Vakil NL. Screening and surveillance for Barrett's esophagus in high risk groups: a cost utility analysis. Ann Intern Med 2003; 138:176-186.
44. Gerson LB, Groeneveld PW, Triadafilopulos G. Cost effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004; 2:868-879.
45. Soni A, Sampliner RE, Sonnenberg A. Screening for high grade dysplasia in gastro-esophageal reflux disease: is it cost effective? Am J Gastroenterol 2000; 95:2086-2093.
46. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Therap 2002; 16:41-54.
47. Gladman L, Chapman W, Iqbal TH, Cooper BT. Barrett's oesophagus: an audit of surveillance over 15 years [Abstract]. Gut 2004; 53:A54.